Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Laura Sahyoun

IBD · WCM

View

Dr. Uma Mahadevan

IBD · UCSF

View

Dr. Deborah Proctor

IBD · Yale College

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Nneka Ufere

Liver Transplant · MGH

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View

Dr. Rushabh Modi

General GI · Kaiser Permanente

View

Dr. Brennan Spiegel

General GI · Cedars-Sinai

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    GMDr. Gil Melmed

    Dr. Gil Melmed

    Gastroenterology · Inflammatory Bowel Diseases
    Cedars-Sinai Medical Center
    gil

    Research

    Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

    2025

    Via BMJ Open Gastroenterology

    Research

    Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment

    2025

    Via Clinical Gastroenterology and Hepatology

    Research

    Long-Term Sustained Improvement in Unplanned Healthcare Utilization in Patients With Inflammatory Bowel Disease

    2025

    Via American Journal of Gastroenterology

    Research

    ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease

    2025

    Via American Journal of Gastroenterology

    Research

    Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis

    2024

    Via Inflammatory Bowel Diseases

    Research

    Measurement Is Necessary But Not Sufficient to Improve Quality of Care for Patients With Inflammatory Bowel Disease

    2024

    Via Journal of Crohn's and Colitis

    Research

    Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons

    2024

    Via Advances in Therapy

    Research

    Imaging in Inflammatory Bowel Disease

    2024

    Via Rheumatic Disease Clinics of North America

    Research

    Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials

    2024

    Via JAMA

    Research

    Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

    2023

    Via Inflammatory Bowel Diseases

    Research

    Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis

    2023

    Via Crohn's & Colitis 360

    Research

    Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis

    2023

    Via Gut

    Research

    Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study

    2023

    Via Gastroenterology

    Research

    Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab

    2022

    Via Clinical Gastroenterology and Hepatology

    Research

    Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review

    2021

    Via Clinical Gastroenterology and Hepatology